

November 8, 2019

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

**The National Stock Exchange of India Limited**  
Exchange Plaza , Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Sirs,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**‘Strides announces relaunch of Ranitidine tablets (Rx) for the US Market’**

Thanks & Regards,  
For **Strides Pharma Science Limited**



**Manjula Ramamurthy**  
**Company Secretary**



*Encl: As Above*

**Strides Pharma Science Limited**

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

**Corp Off:** Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

**Regd Off:** 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com

---

## Strides announces relaunch of Ranitidine tablets (Rx) for the US Market

---

### *Product to be relaunched with immediate effect*

---

**November 08, 2019:** Strides Pharma Science Limited (Strides or company) today announced relaunch of Ranitidine tablets for the US market. USFDA had tested numerous ranitidine tablets on the market over the past few months and released a summary of the results on November 1, 2019. The agency had indicated that if the NDMA levels were above the acceptable limits (96 nanograms per day or 0.32 ppm), they are asking companies to recall ranitidine products voluntarily. **Strides' Ranitidine Tablets 300 mg (Rx) were within the acceptable limits for NDMA of 96 nanograms per day or 0.32 ppm. Strides has now completed comprehensive testing of several of its batches available in market and in stock meeting the limits prescribed by the USFDA. Basis the outcome company has decided to relaunch its product with immediate effect.**

Strides has approvals for Ranitidine tablets USP 150 mg and 300 mg. According to IQVIA MAT data, the US market for Ranitidine tablets USP 150 mg and 300 mg is ~ US\$ 76 Mn. The company also has approvals for several OTC strengths but has not commercialized these products.

### **About Strides**

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com)

### **For further information, please contact:**

#### **Strides**

#### **Badree Komandur**

Executive Director - Finance  
+91 80 6784 0747

#### **Investor Relations:**

**Kannan. N:** +91 98450 54745  
**Vikesh Kumar:** +91 80 6784 0827  
**Sandeep Baid:** +91 80 6784 0791  
Email: [Sandeep.baid@strides.com](mailto:Sandeep.baid@strides.com)

#### **Strides Pharma Science Limited**

(Formerly Strides Shasun Limited)  
CIN: L24230MH1990PLC057062

#### **PR Consultancy**

Fortuna PR  
K Srinivas Reddy: +91 90005 27213  
[srinivas@fortunapr.com](mailto:srinivas@fortunapr.com)

K Priya: +91 95354 25418  
[priya@fortunapr.com](mailto:priya@fortunapr.com)

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi, Navi  
Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,  
Bangalore – 560 076